Allergan bid opens new battlefront for activist funds

The bid by Bill Ackman's Pershing Square and Valeant Pharmaceuticals for Allergan is a seminal moment in M&A and could pave the way for more corporate players to team up with an activist shareholder.

Bill Ackman’s Pershing Square Capital Management has opened a brave new world for activist funds with its move to team up with Valeant Pharmaceuticals to make a hostile takeover offer for botox maker Allergan, say investment bankers and lawyers.

Chris Young, who heads Credit Suisse’s global contested situations team in New York that deals with activist funds, says this pairing to try and acquire a company is a watershed development.


SMS Code Sent…

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Log in to access this content

Looks you are already a member. Please enter your password to proceed

Hi {{ user.FirstName }}

Verify your mobile number to unlock a FREE trial

Looks like you've already taken a free trial

Please sign up for full access

Updating information

Please wait ...

Related Articles